Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma

Table 1 Summary of included trials comparing bevacizumab with interferon (Bev + IFN), sunitinib, and pazopanib to interferon alone (IFN) or one another as first-line therapy for patients with clear cell renal cell carcinoma

Trial	Treatment arms (n)	Overall survival		Progression-free survival		Response
		Median^a	HR (95% CI)	Median^a	HR (95% CI)	Percent	OR (95% CI)
Rini et al. (2008; 2013) [15, 16]	Bev + IFN^b,c (n = 369)	18.3	0.86 (0.73-1.01)	8.5	0.71 (0.61-0.83)	26%	2.27 (1.51-3.42)
Rini et al. (2008; 2013) [15, 16]	IFN^c (n = 363)	17.4	0.86 (0.73-1.01)	5.2	0.71 (0.61-0.83)	13%	2.27 (1.51-3.42)
Escudier et al. (2007; 2010) [17, 18]	Bev + IFN^b,c (n = 327)	23.3	0.86 (0.72-1.04)	10.2	0.61 (0.51-0.73)	31%^f	3.11 (2.04-4.74)
Escudier et al. (2007; 2010) [17, 18]	IFN^c (n = 322)	21.3	0.86 (0.72-1.04)	5.4	0.61 (0.51-0.73)	13%^f	3.11 (2.04-4.74)
Motzer et al. (2013) [19]	Pazopanib^d (n = 557)	28.4	0.91 (0.76-1.08)	8.4	1.05 (0.90-1.22)	31%	1.35 (1.03-1.75)
Motzer et al. (2013) [19]	Sunitinib^e (n = 553)	29.3	0.91 (0.76-1.08)	9.5	1.05 (0.90-1.22)	25%	1.35 (1.03-1.75)
Motzer et al. (2007; 2009) [14]	Sunitinib^e (n = 375)	26.4	0.82 (0.67-1.00)	11	0.54 (0.45-0.64)	47%	6.33 (4.37-9.15)
	IFN^c (n = 375)	21.8		5		12%

ISSN: 1471-2407